Low Libido: Labs, Causes, and Next Steps

How Common Is Low Libido, Really?

Low libido is not a fringe complaint. Population-level data show it is one of the most reported sexual health concerns in both sexes, yet it remains under-diagnosed because patients and clinicians alike often avoid the conversation.

Prevalence in Women

The PRESIDE study (N=31,581) found that 8.9% of U.S. Women aged 18 to 44 met criteria for hypoactive sexual desire disorder (HSDD) when distress was included as a requirement 1. Without the distress criterion, the number reporting low desire climbed above 33%. Rates rise further during perimenopause and postmenopause, when estradiol and testosterone both decline 2.

Prevalence in Men

The European Male Ageing Study (EMAS, N=3,369) reported that 15% of community-dwelling men aged 40 to 79 endorsed low sexual desire 3. That figure jumped to 25% among men with total testosterone below 8 nmol/L (approximately 231 ng/dL). Age-related testosterone decline averages 1 to 2% per year after age 30, compounding the risk over decades 4.

Why It Goes Undiagnosed

A 2016 survey published in the Journal of Sexual Medicine found that only 14% of women with HSDD symptoms had ever been asked about sexual function by their primary care provider 5. The gap is smaller but still significant in men's health settings. If a patient does not volunteer the symptom, it is often missed entirely.

What Causes Low Libido?

The drivers sort into three buckets: hormonal, pharmacological, and psychosocial. Most patients with persistent low desire have more than one contributing factor at the same time, which is why a systematic workup matters.

Hormonal Causes

Testosterone is the primary androgen driving sexual desire in both men and women. In men, the Endocrine Society defines hypogonadism as a total testosterone consistently below 300 ng/dL, combined with symptoms 6. In women, no universal cutoff exists, but several studies associate free testosterone in the lowest quartile with reduced desire 7.

Thyroid dysfunction also plays a role. Both overt hypothyroidism and hyperthyroidism are associated with sexual dysfunction. A cross-sectional study (N=4,000) in the Journal of Clinical Endocrinology & Metabolism found that women with TSH above 4.5 mIU/L were 2.3 times more likely to report low desire compared to euthyroid controls 8.

Hyperprolactinemia suppresses GnRH pulsatility, which in turn lowers gonadal hormone output. Prolactin levels above 25 ng/mL in women or 20 ng/mL in men warrant further investigation 9.

Medication-Induced Causes

SSRIs and SNRIs are the most frequently implicated drug class. A meta-analysis by Serretti and Chiesa (2009) covering 14 studies and over 7,000 patients reported that SSRI-associated sexual dysfunction occurred in 25.8% to 80.3% of users, depending on the specific agent 10. Paroxetine carried the highest risk; bupropion, the lowest.

Other offenders include combined oral contraceptives (via SHBG elevation that binds free testosterone), spironolactone, 5-alpha reductase inhibitors such as finasteride, opioids, and certain antipsychotics. Any medication that raises prolactin or lowers androgens should be considered.

Psychosocial and Lifestyle Factors

Chronic stress elevates cortisol, which competes with gonadal steroid production through the hypothalamic-pituitary-adrenal axis. Poor sleep (fewer than 6 hours per night) has been linked to a 10 to 15% reduction in morning testosterone levels in young men within just one week 11. Relationship dissatisfaction, body image concerns, and a history of sexual trauma all independently lower desire, sometimes more powerfully than any lab value.

Which Labs Should You Order?

A focused lab panel can identify or rule out the most actionable causes. You do not need 30 analytes. You need the right ones drawn at the right time.

The Core Panel

The Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH) recommend starting with these for any patient reporting persistent low desire 6 12:

• Total testosterone (drawn fasting, before 10 AM in men)
• Free testosterone (calculated or measured by equilibrium dialysis)
• Sex hormone-binding globulin (SHBG) (to interpret how much testosterone is bioavailable)
• TSH (to screen for thyroid dysfunction)
• Prolactin (to rule out hyperprolactinemia)

When to Expand the Panel

Add these based on clinical context:

• Estradiol: in perimenopausal or postmenopausal women, or men on aromatase inhibitors
• LH and FSH: when primary vs. Secondary hypogonadism needs differentiation
• DHEA-S: in women with adrenal insufficiency risk factors
• CBC and metabolic panel: if fatigue, anemia, or liver disease may contribute
• HbA1c or fasting glucose: diabetes and insulin resistance are independent risk factors for sexual dysfunction 13
• Iron studies: ferritin below 30 ng/mL is associated with fatigue and reduced desire in premenopausal women

Dr. Sharon Parish, Professor of Medicine in Clinical Psychiatry at Weill Cornell Medicine, has stated: "A thorough sexual medicine evaluation includes a hormonal panel, a medication review, and a psychosocial assessment. You cannot treat what you have not measured" 12.

Timing and Interpretation

Morning draws (before 10 AM) are non-negotiable for testosterone in men because of diurnal variation. A single low value is not diagnostic; the Endocrine Society requires two separate morning draws at least 4 weeks apart before confirming hypogonadism 6. SHBG context matters: a patient with "normal" total testosterone but elevated SHBG may have functionally low free testosterone and symptomatic hypogonadism.

How Is Low Libido Diagnosed?

Diagnosis rests on three pillars: validated patient-reported outcome (PRO) tools, the lab panel above, and ruling out mimics.

Screening Questionnaires

The Decreased Sexual Desire Screener (DSDS) is a 5-item, clinician-administered tool validated for identifying generalized acquired HSDD in women 14. For men, the ADAM (Androgen Deficiency in Aging Males) questionnaire screens for symptomatic hypogonadism, though its specificity is modest at roughly 36% 15.

Clinical Interview

A structured sexual history covers five domains: desire, arousal, orgasm, pain, and satisfaction. The ISSWSH consensus panel recommends asking about onset (lifelong vs. Acquired), context (generalized vs. Situational), and degree of personal distress 12. Situational low desire (present with one partner but not during solo activity) usually points toward relational or psychological factors rather than hormonal ones.

Ruling Out Mimics

Depression. Fatigue syndromes. Chronic pain. All of these reduce sexual interest independently. The 2018 ISSWSH process of care algorithm specifies that clinicians should screen for major depressive disorder, substance use, and intimate partner conflict before attributing low desire solely to endocrine pathology 12.

Evidence-Based Treatments for Low Libido

Treatment selection depends on the identified cause (or causes). A targeted approach outperforms generic advice.

Testosterone Therapy in Men

For men with confirmed hypogonadism (two morning total testosterone values <300 ng/dL plus symptoms), testosterone replacement therapy (TRT) is the first-line intervention. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, confirmed that TRT in men aged 45 to 80 with hypogonadism and cardiovascular risk factors did not increase the rate of major adverse cardiovascular events compared to placebo 16. Improvements in sexual desire were evident by week 4 and sustained at 12 months.

The Testosterone Trials (TTrials, N=790) showed that testosterone gel significantly improved sexual desire scores on the Psychosexual Daily Questionnaire compared to placebo in men over 65, with a mean increase of 0.58 points on a 0-to-3 scale (P<0.001) 17.

Testosterone Therapy in Women

The 2019 Global Consensus Position Statement on Testosterone Therapy for Women, endorsed by the International Menopause Society, supports transdermal testosterone (typically 5 mg daily compounded cream or off-label use of male patches at reduced doses) for postmenopausal women with HSDD who do not respond to non-hormonal management 18. A Lancet meta-analysis (N=8,480 across 36 RCTs) found that testosterone therapy significantly increased the number of satisfying sexual events by 0.85 per 4-week cycle compared to placebo 19.

The consensus statement's lead author, Professor Susan Davis of Monash University, noted: "Transdermal testosterone at physiologic doses is the only evidence-based systemic testosterone therapy for postmenopausal women with low sexual desire causing distress" 18.

FDA-Approved Non-Hormonal Options for Women

Flibanserin (Addyi) is a serotonin 1A agonist and 2A antagonist approved for premenopausal women with acquired, generalized HSDD. In the BEGONIA trial (N=1,087), flibanserin 100 mg at bedtime produced a mean increase of 0.5 satisfying sexual events per month over placebo 20. Side effects include dizziness, somnolence, and nausea. Alcohol must be avoided within 2 hours of dosing.

Bremelanotide (Vyleesi) is a melanocortin-4 receptor agonist administered as a subcutaneous injection at least 45 minutes before anticipated sexual activity. The RECONNECT trials (N=1,247) demonstrated a statistically significant improvement in desire scores on the Female Sexual Function Index compared to placebo 21. It is limited to a maximum of 8 injections per month.

Addressing Medication-Related Causes

Switching from a high-risk SSRI (paroxetine, sertraline) to bupropion, which has the lowest sexual side effect profile among antidepressants, is a well-supported strategy. A randomized controlled trial (N=150) published in Annals of Internal Medicine found that bupropion-treated patients reported sexual dysfunction rates of 22% compared to 67% for sertraline 22.

For patients on combined oral contraceptives with elevated SHBG, switching to a progestin-only method or a non-hormonal contraceptive sometimes restores bioavailable testosterone. This should be discussed with the prescribing clinician before any changes.

Psychotherapy and Lifestyle Interventions

Cognitive behavioral therapy (CBT) adapted for sexual dysfunction and mindfulness-based approaches both have randomized trial support for improving desire, particularly in women 23. Exercise (150 minutes per week of moderate aerobic activity) is associated with improved sexual function scores in both sexes across multiple observational studies. Sleep optimization to at least 7 hours per night addresses one of the most modifiable risk factors for low testosterone.

When Should You Worry About Low Libido?

Not every dip in desire needs a workup. Temporary decreases during periods of high stress, early parenthood, or acute illness are normal. Seek evaluation when the change persists beyond 3 months and causes personal distress or relationship strain.

Red Flags That Warrant Urgent Evaluation

• Sudden-onset loss of desire with galactorrhea (suggests prolactinoma)
• Low libido combined with new visual field changes (pituitary mass effect)
• Low libido in a man under 40 with testicular atrophy (possible primary hypogonadism)
• Loss of desire onset coinciding perfectly with a new medication

Monitoring After Treatment Starts

Once therapy begins, repeat labs at 6 to 12 weeks. For men on TRT, check total testosterone (aiming for a mid-normal range of 450 to 700 ng/dL), hematocrit (hold if above 54%), and PSA at baseline and 3 to 6 months 6. For women on transdermal testosterone, check total testosterone to confirm levels remain within the premenopausal physiologic range, and watch for androgenic side effects such as acne or hirsutism.

Reassess subjective desire using the same PRO tool from baseline. A clinically meaningful change on the FSFI desire domain is approximately 0.4 points. If the patient shows lab improvement without symptom improvement, re-examine psychosocial contributors.